Last Wednesday, we presented the above topic to the Kelantan and East Coast health professionals. The program was a collaboration with Pfizer, and Universiti Sains Malaysia to update the health professionals on data around CDK4/6 inhibitors and consolidate their use as an up-front treatment strategy in metastatic hormone positive, HER2- breast cancer.
We thanked the attendees and we look forward to further educational sessions with everyone.
Navigating CDK 4/6i and Real World Evidence in the Treatment of HR+ / HER2- Metastatic Breast Cancer : Kelantan and East Coast CME
